Biotech Values

[mcbio]

1) treating to late. recent literature suggest that 70% of neurons are dead by the time a patient is diagnised with mild to moderate AD. By the way, same literature also says 45% of neurons are dead by the time a patient has MCI or prodromal: Aysmptomatic (like the genentech crenenzumab trial in columbia) is the way to go.

So, is the gantenerumab (Roche/MorphoSys) trial not testing in asymptomatic? If not, isn't that a bearish sign given your point here?